33 results about "Myocardial function" patented technology

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

A non-invasive diagnostic system assesses the optimal timing for aortic valve replacement (AVR) by quantifying left-ventricular Frank-Starling reserve before irreversible myocardial damage occurs. The system (i) acquires left-ventricular ejection time (LVET) and other systolic-time intervals from optical or vibrational sensors positioned on the patient, (ii) induces a reversible preload change—e.g., passive leg raise or posture transition—to create a controlled venous-return increment, (iii) processes the paired baseline and post-maneuver waveforms to extract systolic time interval metrics, and (iv) analyzes the ΔLVET / Δpreload relationship against historical or population references. A diminished LVET response signals loss of contractile reserve, enabling timely AVR while myocardial changes remain reversible. The platform integrates measurement hardware, a data-processing engine, a data-analysis module, and a reporting interface, and may be configured as a wrist, ring, chest, or ear sensor. The method can be implemented at point-of-care without operator-dependent imaging or invasive monitoring.

The invention discloses application of Zip7 in prevention and / or treatment of sepsis cardiomyopathy. The research finds that after the Zip7 gene is knocked out, the myocardial function of a sepsis mouse can be remarkably improved. It is prompted that Zip7 is a novel treatment approach for preventing and treating sepsis cardiomyopathy.

The invention relates to a nano drug-loaded complex with a targeted myocardial function as well as a preparation method and application of the nano drug-loaded complex. The preparation method comprises the following steps: constructing a novel, safe and efficient nano drug-loaded complex by utilizing a nano material assembly technology, namely preparing phospholipid micelles by taking distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG) as a main raw material, loading fluorescent coumarin 6 (C6), adding ischemia targeting polypeptide CSTSMLKAC (PEP) to be coupled on the outer side of the DSPE-PEG, wrapping an SIRT6 agonist MDL-800 in the DSPE-PEG, and preparing the novel, safe and efficient nano drug-loaded complex. The preparation method comprises the following steps: designing and constructing to obtain a DSPE-PEG-C6-PEP-MDL-800 (DPCP-MDL-800) complex; on the basis, characterization release and in-vivo distribution of the complex and an improvement effect of the complex on myocardial ischemia reperfusion injury of an aged mouse are evaluated. The novel nano drug-loaded complex drug with the ischemic myocardial targeting function provided by the invention is expected to provide a potential solution for myocardial ischemia reperfusion injury of aged mice.

The invention relates to the technical field of coenzyme Q10 preparations, and discloses a coenzyme Q10 preparation for improving myocardial cell activity and cardiovascular function, and the coenzyme Q10 preparation comprises the following components in percentage by mass according to 1 liter of prescription: 0.1-10% of coenzyme Q10, 0.5-30% of emulsifier, 5-20% of co-emulsifier, 0.5-10% of stabilizer, 5% of glucose, 0.9% of sodium chloride, 0.25% of absolute ethyl alcohol and the balance of water, according to the coenzyme Q10 preparation for improving the myocardial cell activity and the cardiovascular function, preparation of the coenzyme Q10 preparation is completed, so that the obtained coenzyme Q10 preparation has the functions of enhancing physical ability and vigor, protecting the cardiovascular system, reducing side effects of lipid-lowering drugs, protecting the skin and the like, and the coenzyme Q10 preparation can improve the myocardial function and improve cardiovascular diseases; the heart is prevented from being damaged by oxidative stress.

The application provides an antisense oligonucleotide Jag-i9 ASO and application thereof, relates to the technical field of biological medicine, and the antisense oligonucleotide Jag-i9 ASO has the sequence of 5'-ACTGGGCCCTGCACCTGA-3'. By providing the antisense oligonucleotide of a specific sequence, the binding site of target heterogeneous ribonucleoprotein K and the Jag2 gene is targeted, the expression of the pro-inflammatory Jag2 subtype is inhibited, the Jag2 gene splicing site can be accurately targeted, the heterogeneous ribonucleoprotein K binding function is specifically blocked, a targeted intervention means is provided for the treatment of myocardial ischemia-reperfusion injury, the generation of the pro-inflammatory subtype is inhibited by efficiently and accurately regulating the alternative splicing of a specific gene, myocardial cell apoptosis and inflammatory response are reduced, myocardial function is improved, and a new approach is provided for the prevention and treatment of myocardial ischemia-reperfusion injury, the treatment effect is improved, and the advantages of reducing side effects are achieved.

The invention provides a coronary heart disease echocardiogram pathological feature extraction method and system. Static structure features and myocardial function features of the heart of a target coronary heart disease patient are determined through an ultrasonic video stream of the heart of the target coronary heart disease patient; determining a region mapping matrix of a relationship between a coronary artery blood supply region of the target coronary heart disease patient and a myocardial injury state according to the static structural characteristics and the myocardial functional characteristics, and determining boundary sharpening development of a pathological region in the heart of the target coronary heart disease patient according to the region mapping matrix; acquiring a myocardial movement track of the target coronary heart disease patient, and determining a longitudinal strain gradient of a basal segment and a cardiac apex segment of the heart of the target coronary heart disease patient according to the myocardial movement track; and based on the boundary sharpening development and the longitudinal strain gradient of the pathological area and in combination with the clinical pathological data of the target coronary heart disease patient, generating the cardiac physical characteristics of the target coronary heart disease patient. According to the scheme, the static structure and the dynamic function of the heart can be effectively associated and fused to extract the coronary heart disease echocardiogram features.

The invention discloses a myocardial amyloidosis quantitative analysis method based on SPECT imaging and related equipment, and relates to the field of wisdom medical device.The method comprises the steps that firstly, three-dimensional SPECT original data of N time phases of a target patient in the cardiac cycle are collected, a mu graph is generated based on low-dose CT for registration and attenuation correction, and a dynamic image is reconstructed; and then an MR structure sequence under synchronous electrocardio gating is obtained, and SPECT and MR space standardization and partial volume effect correction processing are completed. And unifying the cardiac cycle image form through affine and nonlinear transformation, and generating a high-quality enhanced SPECT image. Finally, radioactive counting information is extracted on the basis of three-dimensional segmentation, multiple myocardial quantitative indexes are calculated, comprehensive analysis of myocardial functions is achieved in combination with left ventricular functional parameters, and accurate image support is provided for non-invasive diagnosis and curative effect evaluation of myocardial amyloidosis.

The invention relates to the technical field of pharmaceutical preparations, and particularly provides a cardiac peptide red yeast rice tablet as well as a preparation method and application thereof. The cardiac peptide red yeast rice tablet comprises the following components: cardiac peptide powder, soybean peptide powder, functional red yeast rice, D-mannitol, bovine heart peptide powder, microcrystalline cellulose, a compound nutrition enhancer and magnesium stearate. According to the cardiac peptide red yeast rice tablet disclosed by the invention, the components are used according to a specific ratio, so that the cardiac peptide red yeast rice tablet has the functions of preventing myocardial dysfunction caused by lipid metabolism disorder, improving myocardial contractility and increasing the survival rate of myocardial cells, and a product suitable for improving cardiac functions can be provided.

The invention discloses a method for adjusting coronary artery display and an ultrasonic imaging system. The method comprises the following steps: acquiring an ultrasonic image of the heart of a target object; obtaining myocardial function parameters of a plurality of myocardial segments of the heart based on the ultrasonic image; a bull eye diagram segment model is obtained, the bull eye diagram segment model comprises myocardial segment areas in one-to-one correspondence with the myocardial segments, and the myocardial segment areas comprise myocardial function parameters corresponding to the myocardial segments; a preset coronary artery graph is obtained, and the preset coronary artery graph and the bull eye graph segment model are displayed in an overlapped mode; adjusting the preset coronary artery graph to obtain a coronary artery graph matched with the coronary artery deformation of the target object; and displaying the adjusted preset coronary artery graph and the bull eye graph segment model in an overlapping manner. According to the scheme, the preset coronary artery graph and the bullseye diagram segment model are displayed in an overlapped mode, the control assembly is used for adjusting the preset coronary artery graph so that the coronary artery graph can be matched with the coronary artery deformation of the target object, combined display of the bullseye diagram and the coronary artery structure is achieved, and the diagnosis efficiency and accuracy of doctors are improved.

The invention belongs to the technical field of pharmacy, and particularly relates to application of spermidine in sepsis treatment. Experiments prove that spermidine can regulate mitochondrial biogenesis and inhibit mitochondrial excessive autophagy to remarkably improve mitochondrial quality, maintain mitochondrial homeostasis and relieve myocardial dysfunction and heart structure damage. In addition, spermidine can inhibit oxidative stress caused by excessive inflammatory response so as to recover normal functions of mitochondria. The spermidine has a potential treatment effect on sepsis and has a good clinical application prospect in treating sepsis and related diseases caused by excessive autophagy.

The present application relates to the use of D-ribose in a subject with accumulated exercise-induced fatigue. D-ribose helps to improve and / or protect the myocardial function of the subject, increase the myocardial hypoxia tolerance of the subject, improve and / or protect the skeletal muscle function of the subject, reduce the risk of inflammation in the subject, improve the exercise performance and exercise tolerance of the subject, and / or accelerate recovery from exercise-induced fatigue.

A system and method for monitoring a patient's blood flow waveform require a pulse oximeter to non-invasively measure changes in parametric and blood flow measurements of the waveform. These parametric measurements, namely changes in diastolic pressure, ±Δpd, changes in systolic pressure, ±Δps, and changes in pulse time rate, ±Δtr, collectively affect the patient's blood flow volume. Thus, they can also be used, collectively, to assess the patient's heart muscle function as an indicator of his / her health condition.

The invention relates to the technical field of food biology, in particular to a high-activity fermented astragalus mongholicus and red date compound for improving myocardial function, which is prepared by taking Xinjiang Qiang red dates and astragalus mongholicus as main raw materials and matching cellulase, pectinase, beta-glucanase and hydroxypropyl-beta-cyclodextrin. In the preparation process, gradient freezing-microwave pretreatment and ternary composite enzymolysis synergistic wall breaking are adopted, quaternary strains of bifidobacterium longum, bacillus subtilis, saccharomyces cerevisiae and lactobacillus plantarum are compounded, adenosine concentration response type staged solid-state fermentation is performed, and microcapsule embedding stabilizing treatment is performed to obtain the product. The content of cAMP in the product is greater than or equal to 13.0 mu g / g, and the content of calycosin-7-glucoside in astragalus membranaceus is greater than or equal to 1.9 mg / g. The compound can be used for preparing myocardial ischemia pretreatment health-care food and a pharmaceutical composition for adjuvant therapy in the myocardial infarction recovery period, and the dosage forms comprise chewable tablets, oral liquid, capsules and the like.

The present invention relates to a composition for preventing or treating diabetic cardiomyopathy comprising an MsrB2 activator as an active ingredient. The MsrB2 activator disclosed in the present invention suppresses oxidative damage of ROS, induces autophagy in mitophagy, increases mitochondrial regeneration and biosynthesis in diabetic heart tissue, thereby suppressing overall myocardial function decline, so that it can be effectively used in a pharmaceutical composition or health food composition for preventing or treating diabetic cardiomyopathy, particularly diabetic heart disease in lean diabetes.

Provided are: cardiomyocytes with which, by overexpressing NCAM1 in iPS cell-derived cardiomyocytes, iPS cell-derived cardiomyocytes having high adhesion ability can be obtained, and by producing EHT using the same, the organization of the EHT can be further promoted and the function of the EHT can be enhanced; a cellular tissue-like structure; and a method for improving the function of cardiomyocytes. Provided are cardiomyocytes into which an expression vector of an NCAM1 protein has been introduced. Moreover, provided are: a cellular tissue-like structure comprising said cardiomyocytes; and a method for improving the function of cardiomyocytes, the method comprising a step for inducing the expression of an NCAM1 protein in cardiomyocytes.

The invention provides saffron crocus direct drinking powder as well as a preparation method and application thereof. The saffron crocus direct drinking powder is prepared from the following raw materials: saffron crocus extract, cardiomyopeptide powder, menthol, citric acid, erythritol, maltodextrin and cranberry powder. The saffron crocus direct drinking powder disclosed by the invention has excellent free radical scavenging capacity and myocardial protection function, so that the problems in the aspect of heart and cerebral vessels of a human body are solved, a brand-new way can be provided for treatment of cardiovascular diseases, and the occurrence risk of adverse reactions can be reduced while the treatment effect is improved. In addition, the product also has a good taste and is easily accepted by people.

The invention discloses an application of Fc-Elabeta-32 in preparation of a medicine for treating sepsis, and also comprises a preparation method of the Fc-Elabeta-32, and the preparation method comprises the step of fusing an Fc structural domain of human immune globulin IgG with Ela-32 to generate the Fc-Ela-32. The application has the advantages that by preparing and using the Fc-Elabel-32, the survival rate of sepsis mice is remarkably increased in an experiment, the cardiac function is remarkably improved, meanwhile, the myocardial injury index is remarkably reduced, myocardial dysfunction caused by sepsis is relieved, and the Fc-Elabel-32 can be used as a potential treatment medicine for sepsis.

The application discloses a compound preparation beneficial to muscle nutrition, which is composed of yeast extract powder, yeast beta-1, 3-glucan and ginsenoside at a weight ratio of 8:1:1, and contains 200-800 mg of yeast extract powder in each unit of the preparation; wherein the essential amino acids beneficial to muscle nutrition include three branched-chain amino acids, specifically isoleucine, leucine and valine, and the ratio coefficient of the branched-chain amino acids is 1-1.2, and the ratio coefficient range is 0.94-1.14. The compound preparation can improve the symptoms caused by muscle attenuation syndrome, such as muscle weakness, osteoporosis and myocardial function degradation, has the advantages of easy absorption, high safety, synergistic effect and the like, and is suitable for the old, the weak and the people with decreased sports ability.

The invention relates to an application of D-ribose in a cumulative exercise fatigue subject, which is beneficial to improving and / or protecting the myocardial function of the subject, improving the myocardial hypoxia tolerance of the subject, improving and / or protecting the skeletal muscle function of the subject, reducing the inflammation occurrence risk of the subject, and improving the exercise performance ability and exercise tolerance of the subject. And / or accelerating exercise fatigue recovery.

This invention discloses a method and system for predicting the prognosis of myocardial function in sepsis based on imidazole propionate targeted intervention. The method includes: firstly, collecting baseline characteristic data of sepsis patients and dynamic response data after imidazole propionate targeted intervention, and simultaneously recording time parameters from sepsis diagnosis to intervention initiation. Then, transforming the data according to preset standardization rules to obtain metabolic characteristics, myocardial function comprehensive data, mitochondrial function comprehensive data, and intervention response parameters, filtering out abnormal data and retaining valid data. Subsequently, the standardized data are substituted into a multi-parameter nonlinear weighted model fusing exponential and logistic regression functions to simultaneously calculate myocardial function recovery assessment values ​​and adverse prognostic risk values. Finally, based on the assessment results, prognostic grade intervals are defined, and differentiated intervention plans are formulated to complete the closed-loop treatment optimization of "prediction-intervention-dynamic reassessment." This improves the targeting and effectiveness of clinical diagnosis and treatment.

The invention relates to ERLIN2 variants and a method for screening potential drugs. Specifically, the invention provides application of ERLIN2 as a target spot in screening potential substances for preventing or treating myocardial contraction and / or diastolic function impairment. The invention discovers that the biological clock protein CRY1 / 2 regulates the mitochondrial function through ERLIN2 and regulates the myocardial function for the first time.

The invention relates to the technical field of myocardial function evaluation, and discloses a myocardial function evaluation method and device, a storage medium and computer equipment, and the method comprises the steps: applying acupuncture stimulation to a target object, and collecting a multi-channel magnetocardiogram signal and various physiological data of the target object; fusing the various physiological data and the multichannel magnetocardiogram signal to generate a physiological signal set, so as to dynamically adjust the load parameter of acupuncture stimulation; performing time alignment and space fusion on the multi-channel magnetocardiogram signal by using a multi-channel deep fusion network to obtain a multi-dimensional magnetocardiogram signal, and extracting feature information by using a deep learning feature extraction network; after the feature information and the multiple physiological data are fused, a cardiac load evaluation model is used for evaluating the myocardial function state of the target object, and the cardiac load capacity and / or the cardiac blood pumping efficiency are / is obtained. According to the method, the acupuncture load and the magnetocardiogram technology are combined, the myocardial function is dynamically, continuously and accurately evaluated, and a reliable basis is provided for clinical decision making.

This invention relates to a myocardial repair patch based on multi-material printing, its preparation, and its application, belonging to the field of bio-3D printing and regenerative medicine technology. The invention uses PLCL and GelMA hydrogel loaded with active cardiomyocytes as bio-inks, and introduces gelatin gel as a heat buffer material. An orthogonal network structure is constructed using multi-material bio-3D printing technology to prepare a myocardial repair patch with excellent dynamic adaptability to the myocardial interface and good biocompatibility. The myocardial injury repair patch prepared by this invention achieves a structure-function integrated design through the synergistic effect of the three materials, significantly overcoming the limitations of single materials in terms of mechanical properties, biological function, or thermal compatibility. The mechanical properties of the myocardial injury repair patch prepared by this invention can precisely match those of natural myocardium, while possessing high cell activity, effectively inhibiting fibrosis, improving myocardial function, and achieving true active repair. Furthermore, the process conditions are controllable, demonstrating good translational potential.

This invention discloses the application of NT5C1A as a therapeutic target for myocardial ischemia-reperfusion injury, belonging to the field of biomedical technology. Through proteomics screening and in vitro and in vivo experiments, this invention is the first to discover and demonstrate that NT5C1A is upregulated in the pathological process of MIRI, and is a key upstream factor regulating the AMPK / SIRT1 / PGC-1α signaling pathway. Overexpression of NT5C1A can effectively activate this pathway, synergistically regulating multiple downstream pathological processes: promoting the expression of mitochondrial fusion proteins Mfn-2 and OPA1, inhibiting the expression of the splitting protein DRP1; significantly promoting ATP production and improving energy metabolism disorders; and regulating the balance of apoptosis-related protein Bax / Bcl-2 expression, inhibiting cardiomyocyte apoptosis, ultimately reducing myocardial damage, improving myocardial function, and reducing the infarct area. This invention provides a new target and strategy for the precise intervention of MIRI.

The invention discloses a multi-mode epicardial fat and coronary artery calcification SPECT-CT image classification method and system. The method comprises the following steps: acquiring non-enhanced heart CT three-dimensional voxel data of a one-stop SPECT-CT; dividing the preprocessed CT three-dimensional voxel data by adopting threshold segmentation and connected domain analysis to obtain a coronary artery calcification region and an epicardial fat region; according to the coronary artery calcification region and the epicardial fat region, respectively calculating an Agatston calcification integral CACS, an epicardial fat volume and an epicardial fat density MEAN; according to the Agatston calcification integral CACS, the epicardial fat volume and the epicardial fat density MEAN, algorithm construction is conducted on the non-enhanced same-machine heart CT image through a pre-trained disordered multi-classification logistic regression model, image classification is conducted on SPECT-CT MPI, and the classification probability of four coronary artery structure-myocardial function combination categories is obtained; the method is only based on the non-enhanced heart CT scanning image, and the efficiency of one-stop SPECT-CT MPI image classification is improved.

The present invention provides a pharmaceutical composition used in a method for treating patients with single ventricle heart disease (SVHD) who have undergone the Fontan procedure. [Solution] A pharmaceutical composition for use in a method of treating a patient with SVHD to improve exercise capacity determined by improvement in the patient's VO2max and VO2 at the anaerobic threshold, wherein the SVHD patient has undergone Fontan surgery, and the method comprises administering to the SVHD patient an effective daily dose of the udenafil or a pharmaceutically acceptable salt thereof to treat the SVHD patient to improve exercise capacity determined by improvement in the patient's VO2max and VO2 at the anaerobic threshold, wherein the udenafil or a pharmaceutically acceptable salt thereof is administered in a total daily dose of about 175 mg.

The invention discloses a sepsis myocardial function prognosis prediction method and system based on imidazole propionic acid targeted intervention, and the method comprises the steps: firstly collecting baseline characteristic data of a sepsis patient and dynamic response data after imidazole propionic acid targeted intervention, and synchronously recording time parameters from sepsis diagnosis to intervention starting; and converting the data according to a preset standardization rule to obtain metabolic characteristics, myocardial function integration, mitochondrial function integration and intervention response parameters, screening and removing abnormal data, and reserving effective data. And then substituting the standardized data into a multi-parameter nonlinear weighted model fusing an exponential function and a logistic regression function, and synchronously calculating a myocardial function recovery evaluation value and a poor prognosis risk value. And finally, a prognosis level interval is delimited according to an evaluation result, a differential intervention scheme is formulated, and closed-loop treatment optimization of'prediction-intervention-dynamic reevaluation 'is completed. And the pertinence and effectiveness of clinical diagnosis and treatment are improved.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating heart blood stasis type arrhythmia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 250 to 370 parts of radix codonopsis, 55 to 100 parts of radix notoginseng, 350 to 500 parts of rhizoma polygonati, 150 to 230 parts of rhizoma nardostachyos and 100 to 200 parts of poria cocos. The traditional Chinese medicine composition disclosed by the invention consists of five medicinal materials, namely codonopsis pilosula, pseudo-ginseng, rhizoma polygonati, rhizoma nardostachyos and poria cocos, has good effects of improving myocardial dysfunction, relieving myocardial cell injury and apoptosis and regulating cardiac troponin activity, and can be used for treating heart blood stasis type arrhythmia.

The invention relates to the technical field of biological medicine, and discloses a ginseng composition for improving myocardial function as well as a preparation method and application thereof. The ginseng composition comprises the following components in parts by mass: 9-11 parts of a ginseng extract, 14-16 parts of astragalus membranaceus powder, 11-13 parts of spina date seed powder, 5-7 parts of earthworm protein powder, 5-7 parts of natto powder, 9-11 parts of radix ophiopogonis powder, 5-7 parts of schisandra chinensis powder, 9-11 parts of poria cocos powder, 5-7 parts of liquorice powder, 7-9 parts of polygala tenuifolia powder, 5-7 parts of rhizoma acori graminei powder and 9-11 parts of asparagus cochinchinensis powder. In the scheme, the ginseng extract is combined with the various traditional Chinese medicine components with the cardiovascular regulation function, and all the components generate a comprehensive regulation effect on the myocardial function through a synergistic effect; the ginseng composition can be prepared into capsules, tablets, pills, powder and oral liquid, and is convenient to eat.